There are currently 127 active clinical trials seeking participants for Major Depressive Disorder research studies. The states with the highest number of trials for Major Depressive Disorder participants are California, Florida, Texas and New York.
Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine
NCT05327699
Recruiting
The main purpose of this study is to investigate the effects of ketamine on decision-making and emotion processing in a sample of individuals diagnosed with Major Depressive Disorder (MDD).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/18/2025
Locations: Emory University, Atlanta, Georgia
Conditions: Major Depressive Disorder
Register for Updates
Pain and Major Depressive Disorder
NCT04556890
Recruiting
This study will examine the effects of brain stimulation on pain symptoms associated with Major depressive disorder. This study will enroll 54 Subjects. Study subjects will be asked to complete surveys about their mood and well-being, 2 blood draws, 2 MRIs, 3 electroencephalograms, and receive 30 treatments of blinded transcranial magnetic stimulation. There is no control group as all subjects will receive some form of active treatment. Subjects are required to participate in 30-33 study visits... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/17/2025
Locations: UCLA Semel Institute, Los Angeles, California
Conditions: Major Depressive Disorder, Chronic Pain
Register for Updates
Two Doses of Psilocybin for the Treatment of MDD in Adults With Cancer
NCT05947383
Recruiting
This is a Phase 2, single-center study to explore the efficacy, safety, and tolerability of up to two 25-mg doses of psilocybin administered at an interval of 9 to 10 weeks in patients with MDD and cancer. This two-part study will administer a fixed dose (25 mg) of psilocybin in a double-blind, randomized, placebo-controlled portion (Dosing Session 1) and subsequently allow rollover into an open-label portion (Dosing Session 2; fixed dose of psilocybin, 25 mg) for patients who do not achieve rem... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Sunstone Medical, PC, Rockville, Maryland
Conditions: Cancer, Major Depressive Disorder
Register for Updates
Concurrent fMRI-guided rTMS and Cognitive Therapy for the Treatment of Major Depressive Episodes
NCT03289923
Recruiting
Background: Repetitive transcranial magnetic stimulation (rTMS) is a treatment for depression. It stimulates the brain. Researchers want to see if using magnetic resonance imaging (MRI) scans helps locate the best area for rTMS in each person. They also want to find other ways to make it more effective. Objective: To study the effects of combining MRI- guided transcranial magnetic stimulation (TMS) and talk therapy on the brain in people with depression. Eligibility: Adults ages 18-75 with... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/16/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Major Depressive Disorder
Register for Updates
Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
NCT06058013
Recruiting
This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 28 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/16/2025
Locations: Neumora Investigator Site, Encino, California +66 locations
Conditions: Major Depressive Disorder
Register for Updates
A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)
NCT06941844
Recruiting
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Major Depressive Disorder - Emerge
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
04/16/2025
Locations: Preferred Research Partner, Fayetteville, Arkansas +22 locations
Conditions: Major Depressive Disorder
Register for Updates
Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder
NCT06058039
Recruiting
This randomized, double-blind, placebo-controlled, multicenter study will evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 35 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and mee... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/16/2025
Locations: Neumora Investigator Site, Cerritos, California +66 locations
Conditions: Major Depressive Disorder
Register for Updates
Maintenance rTMS for Depression (Maitr-De)
NCT06938841
Recruiting
Repetitive transcranial magnetic stimulation (rTMS) has emerged as a promising intervention for treatment-resistant depression (TRD), yet substantial uncertainties persist regarding its efficacy as a maintenance treatment. This prospective study seeks to investigate the efficacy of maintenance rTMS in individuals with TRD who have previously responded to an acute course of rTMS. In the R61 phase of the study, we will recruit 75 participants across three study sites, the University of California... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/14/2025
Locations: University of California, San Diego, San Diego, California +2 locations
Conditions: Major Depressive Disorder, Treatment Resistant Depression
Register for Updates
A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder
NCT05593029
Recruiting
This is a Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Flexible Doses of SEP-363856 as Adjunctive Therapy in the Treatment of Adults with Major Depressive Disorder (MDD)
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/11/2025
Locations: For additional information regarding sites, contact 844-687-8522, New York, New York
Conditions: Major Depressive Disorder
Register for Updates
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
NCT03973268
Recruiting
Background: Most drugs that treat mood disorders take a long time to work. Ketamine works within hours. A dose can last for a week or more. Certain receptors in the brain might help ketamine work. A drug that blocks these receptors might affect how it works. Objective: To see if the antidepressant response of ketamine is linked to AMPA receptors. Eligibility: Adults ages 18-70 with major depression disorder without psychotic features Design: Participants will be screened under protocol 01... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/11/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Depression, Major Depressive Disorder, Major Depression
Register for Updates
Identifying Cerebral Hemodynamic Patterns in Mood Disorders and Mild Cognitive Impairment: A Functional Near-Infrared Spectroscopy (fNIRS) Study
NCT06897670
Recruiting
The purpose of this research is to measure brain activity in individuals with mood disorders and memory problems using a simple, safe, and noninvasive method called functional near-infrared spectroscopy (fNIRS). By comparing brain activity across different groups and relating it to symptom severity, this study aims to improve our understanding of how these conditions affect the brain.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Major Depressive Disorder, Bipolar Disorder, Mild Cognitive Impairment
Register for Updates
Alexithymia Intervention for Suicide
NCT05724953
Recruiting
Suicide rates among Veterans with Serious Mental Illness (SMI) are intractably high, representing a serious public health concern and a critical target for interventions. Yet, at present available treatments offer modest benefits. Thus, there remains an urgent need to identify novel approaches to address suicide risk in this population. Previous reports have linked suicide risk with poor social functioning. Emerging evidence from basic affective neuroscience research has indicated that effective... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: James J. Peters VA Medical Center, Bronx, NY, Bronx, New York
Conditions: Suicide, Schizophrenia, Bipolar Disorder, Post Traumatic Stress Disorder, Major Depressive Disorder
Register for Updates